Early detection of anthracycline-induced cardiotoxicity

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-10-12 DOI:10.1016/j.cca.2024.120000

Weimin Feng, Qingchen Wang, Yuan Tan, Jiao Qiao, Qi Liu, Boxin Yang, Shuo Yang, Liyan Cui

引用次数: 0

Abstract

Although anthracyclines are important anticancer agents, their use is limited due to various adverse effects, particularly cardiac toxicity. Mechanisms underlying anthracycline-induced cardiotoxicity (AIC) are complex. Given the irreplaceable role of anthracyclines in treatment of malignancies and other serious diseases, early monitoring of AIC is paramount. In recent years, multiple studies have investigated various biomarkers for early detection of AIC. Currently, the two most common are cardiac troponin and B-type natriuretic peptide. In addition, a range of other molecules, including RNAs, myeloperoxidase (MPO), C-reactive protein (CRP), various genes, and others, also play roles in AIC prediction. Unfortunately, current research indicates a need to validate their sensitivity and specificity of these biomarkers especially in large study populations. In this review, we summarize the mechanisms and potential biomarkers of AIC, although some remain preliminary.

查看原文本刊更多论文

早期检测蒽环类药物引起的心脏毒性

虽然蒽环类是重要的抗癌药物，但由于其各种不良反应，尤其是心脏毒性，其使用受到了限制。蒽环类药物诱发心脏毒性（AIC）的机制十分复杂。鉴于蒽环类药物在治疗恶性肿瘤和其他严重疾病中不可替代的作用，早期监测 AIC 至关重要。近年来，多项研究对用于早期检测 AIC 的各种生物标志物进行了调查。目前，最常见的两种生物标志物是心肌肌钙蛋白和 B 型钠尿肽。此外，包括 RNA、髓过氧化物酶 (MPO)、C 反应蛋白 (CRP)、各种基因等在内的一系列其他分子也在 AIC 预测中发挥作用。遗憾的是，目前的研究表明需要验证这些生物标志物的敏感性和特异性，尤其是在大型研究人群中。在这篇综述中，我们总结了 AIC 的机制和潜在生物标志物，尽管其中一些仍是初步的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.